The 32 most recent market catalysts affecting $JAZZ, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 55
Goldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target
Goldman Sachs analyst Andrea Newkirk has reinstated coverage on Jazz Pharmaceuticals (JAZZ) with a 'Buy' rating and a $337 price target. This analyst action is a positive signal fo…
Sep 11, 2026
Corporate Catalyst
Bullish
Impact 55
UBS Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $337
UBS analyst Ashwani Verma has maintained a 'Buy' rating on Jazz Pharmaceuticals and raised the price target from $315 to $337. This action signals continued bullish sentiment from …
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 85
Jazz Pharmaceuticals shares are trading higher after the company announced second interim top-line overall survival results from the Phase 3 HERIZON-GEA-01 trial.
The positive second interim top-line overall survival results from the Phase 3 HERIZON-GEA-01 trial are a major positive for Jazz Pharmaceuticals. This data suggests the drug is ef…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 85
Jazz Reports Ziihera Outperformed Standard Treatment In Late-Stage Cancer Trial
Jazz Pharmaceuticals reported that its drug Ziihera demonstrated statistically significant and clinically meaningful improvements in overall survival compared to the current standa…
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 55
Deutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300
Deutsche Bank analyst David Hoang has maintained a 'Buy' rating on Jazz Pharmaceuticals and raised the price target from $287 to $300. This action signals a continued bullish outlo…
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $322
Morgan Stanley analyst Jeffrey Hung has raised the price target for Jazz Pharmaceuticals (JAZZ) from $283 to $322, while maintaining an 'Overweight' rating. This upgrade in price t…
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $281
Truist Securities analyst Gregory Renza has maintained a 'Buy' rating on Jazz Pharmaceuticals (JAZZ) and raised the price target from $264 to $281. This action signals a positive o…
Aug 26, 2026
Corporate Catalyst
Neutral
Impact 65
Jazz Pharmaceuticals Announces Private Offering Of $1B Of Exchangeable Senior Notes Due 2032; Expects To Repurchase Up To $225M Of Stock From Note Buyers In Privately Negotiated Transactions
Jazz Pharmaceuticals is raising $1 billion through an offering of exchangeable senior notes, a common financing strategy for companies. The key aspect here is the concurrent plan t…
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 55
Needham Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $310
Needham analyst Ami Fadia maintained a 'Buy' rating on Jazz Pharmaceuticals and raised the price target from $292 to $310. This analyst action signals continued positive sentiment …
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 85
Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens
Jazz Pharmaceuticals has secured FDA approval for two Ziihera (zanidatamab-hrii) combination regimens for a significant oncology indication: first-line treatment for advanced HER2-…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 85
Jazz Pharmaceuticals shares are trading higher after the company received FDA approval for two regimens that contain Ziihera for first-line treatment of adults with gastroesophageal adenocarcinoma.
This FDA approval is a significant positive catalyst for Jazz Pharmaceuticals, as it expands the indications for Ziihera into the first-line treatment of gastroesophageal adenocarc…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 75
Jazz Pharmaceuticals' Two Ziihera-Containing Regimens Receives FDA Approval To Treat Adults With Unresectable Locally Advanced Or Metastatic Her2-Positive Gastroesophageal Adenocarcinoma
Jazz Pharmaceuticals received FDA approval for two Ziihera-containing regimens for the first-line treatment of HER2-positive gastroesophageal adenocarcinoma. This is a significant …
Aug 11, 2026
Market Technicals
Bullish
Impact 55
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $283
Morgan Stanley analyst Jeffrey Hung has maintained an 'Overweight' rating on Jazz Pharmaceuticals and raised the price target from $280 to $283. This action signals continued confi…
Aug 10, 2026
Corporate Catalyst
Neutral
Impact 95
Jazz Pharmaceuticals To Acquire Developer Of Epilepsy Therapy Biotech Actio Biosciences For $820M Up Front And Up To $500M In Contingencies
Jazz Pharmaceuticals is acquiring Actio Biosciences, a biotech company, for an upfront payment of $820 million and up to $500 million in potential milestone payments. This deal is …
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $276
JP Morgan analyst Jessica Fye maintained an 'Overweight' rating on Jazz Pharmaceuticals (JAZZ) and raised the price target from $265 to $276. This action signals continued bullish …
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $264
This filing indicates that Truist Securities analyst Gregory Renza has maintained a 'Buy' rating on Jazz Pharmaceuticals (JAZZ) and raised the price target from $254 to $264. This …
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 55
TD Cowen Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300
TD Cowen's analyst Joseph Thome maintained a 'Buy' rating on Jazz Pharmaceuticals and raised the price target from $275 to $300. This indicates a positive outlook from a prominent …
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $300
Wells Fargo analyst Mohit Bansal has maintained an 'Overweight' rating on Jazz Pharmaceuticals and raised the price target from $285 to $300. This action signals continued confiden…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $280
Morgan Stanley analyst Jeffrey Hung has raised the price target for Jazz Pharmaceuticals (JAZZ) from $245 to $280, while maintaining an 'Overweight' rating. This action signals inc…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 55
Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $310
Piper Sandler analyst David Amsellem maintained an 'Overweight' rating on Jazz Pharmaceuticals (JAZZ) and raised the price target from $301 to $310. This action signals continued b…
Aug 4, 2026
Corporate Catalyst
Neutral
Impact 85
These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results
Jazz Pharmaceuticals' Q2 results showed a significant beat on sales and a substantial increase in its FY26 sales guidance, signaling robust commercial execution and future growth p…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 55
Needham Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $292
Needham analyst Ami Fadia maintained a 'Buy' rating on Jazz Pharmaceuticals and raised the price target from $282 to $292. This action reflects an analyst's updated positive outloo…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $270
Barclays analyst Etzer Darout maintained an 'Overweight' rating on Jazz Pharmaceuticals and raised the price target from $260 to $270. This action signals continued confidence in t…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 55
Baird Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $280
Baird analyst Joel Beatty maintained an Outperform rating on Jazz Pharmaceuticals and raised the price target from $252 to $280. This action signals a strengthened positive outlook…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 92
Jazz Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY26 sales guidance above estimates.
This headline represents a major corporate catalyst for Jazz Pharmaceuticals. The better-than-expected Q2 sales indicate strong current product demand, while the raised FY26 sales …
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 75
Jazz Pharmaceuticals Raises FY2026 Sales Guidance from $4.250B-$4.500B to $4.600B-$4.750B vs $4.517B Est
Jazz Pharmaceuticals announced an upward revision to its FY2026 sales guidance, moving the range from $4.250 billion-$4.500 billion to $4.600 billion-$4.750 billion. This new guida…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 85
Jazz Pharmaceuticals Q2 Adj. EPS $5.71 Misses $6.18 Estimate, Sales $1.208B Beat $1.115B Estimate
Jazz Pharmaceuticals' Q2 earnings report shows a mixed financial picture. While the company's sales of $1.208 billion significantly beat analyst estimates and represent a strong 15…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 55
Needham Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $282
Needham analyst Ami Fadia maintained a 'Buy' rating on Jazz Pharmaceuticals and raised the price target from $255 to $282. This action indicates an analyst's increased confidence i…
Jul 17, 2026
Corporate Catalyst
Neutral
Impact 65
Canaccord Genuity Initiates Coverage On Jazz Pharmaceuticals with Buy Rating, Announces Price Target of $290
Canaccord Genuity analyst Gary Nachman has initiated coverage on Jazz Pharmaceuticals (JAZZ) with a 'Buy' rating and a $290 price target. This event is a positive catalyst for JAZZ…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $285
Wells Fargo analyst Mohit Bansal has maintained an 'Overweight' rating on Jazz Pharmaceuticals (JAZZ) and raised the price target from $265 to $285. This action signals a positive …
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $260
Barclays analyst Etzer Darout has maintained an 'Overweight' rating on Jazz Pharmaceuticals and modestly raised the price target from $253 to $260. This action signals continued co…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.